A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications

PHASE4RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

December 18, 2024

Primary Completion Date

June 5, 2026

Study Completion Date

June 5, 2026

Conditions
Migraine
Interventions
DRUG

Eptinezumab

Solution for infusion

Trial Locations (22)

12230

RECRUITING

Albany Medical College, Albany

14226

RECRUITING

Dent Neurosciences Research Center, Inc., Amherst

15236

RECRUITING

Preferred Primary Care Physicians, Inc., Pittsburgh

19107

RECRUITING

Thomas Jefferson University, Philadelphia

30328

RECRUITING

PANDA Neurology and Atlanta Headache Specialists, Atlanta

33176

RECRUITING

Brainstorm Research, Miami

33407

RECRUITING

Premiere Research Institute at Palm Beach Neurology, West Palm Beach

37067

RECRUITING

KCA Neurology, PLLC, Franklin

44109

RECRUITING

C7 Research, Cleveland

44718

RECRUITING

NeuroScience Research Center, LLC., Canton

48867

RECRUITING

Memorial Healthcare, Owosso

60657

RECRUITING

Chicago Headache Center & Research Institute, Chicago

70115

RECRUITING

Crescent City Headache and Neurology, New Orleans

80138

RECRUITING

Research of the Rockies, Parker

80501

RECRUITING

Advanced Neurology of Colorado, LLC, Longmont

83642

RECRUITING

St Luke's Meridian Medical Center, Meridian

92069

RECRUITING

The Neuron Clinic, San Marcos

93710

RECRUITING

Neuropain Medical Center, Fresno

94596

RECRUITING

Sunwise Clinical Research, LLC., Oakland

06905

RECRUITING

New England Institute for Neurology and Headache, Stamford

02472-3930

RECRUITING

MedVadis Research Corporation, Watertown

75206-5202

RECRUITING

Texas Neurology, PA, Dallas

All Listed Sponsors
lead

H. Lundbeck A/S

INDUSTRY

NCT06701526 - A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications | Biotech Hunter | Biotech Hunter